Dicerna Pharmaceuticals, Inc.
DRNA
DRNA was delisted on the 27th of December, 2021.
112 hedge funds and large institutions have $840M invested in Dicerna Pharmaceuticals, Inc. in 2019 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 29 increasing their positions, 33 reducing their positions, and 13 closing their positions.
21,300% more call options, than puts
Call options by funds: $214K | Put options by funds: $1K
115% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 13
14% more funds holding
Funds holding: 98 → 112 (+14)
7% less capital invested
Capital invested by funds: $901M → $840M (-$60.9M)
12% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 33
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$25.2M |
| 2 |
CTA
Carillon Tower Advisers
St. Petersburg,
Florida
|
+$16M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$10.3M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
+$9.24M |
| 5 |
Renaissance Technologies
New York
|
+$6.94M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BM
Bridger Management
New York
|
-$21.6M |
| 2 |
UONDDL
University of Notre Dame du Lac
South Bend,
Indiana
|
-$12M |
| 3 |
Goldman Sachs
New York
|
-$7.88M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$6.06M |
| 5 |
Millennium Management
New York
|
-$5.56M |
DRNA Hedge Fund Activity: Q3 2019 in Review
112 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Dicerna Pharmaceuticals, Inc. (DRNA) for Q3 2019, worth a combined $840M — down 6.8% from $901M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new DRNA positions and 13 closed out — a net gain of 15 holders — while 29 added to existing stakes and 33 trimmed.
The largest buyer was Eagle Asset Management, opening a new position worth an estimated $25.2M. The largest seller was Bridger Management, cutting an estimated $21.6M.
- 112 institutional investors held Dicerna Pharmaceuticals, Inc. (DRNA) as of Q3 2019, up from 98 in Q2 2019.
- Funds reported $840M of Dicerna Pharmaceuticals, Inc. stock for Q3 2019, down 6.8% quarter-over-quarter.
- 28 funds opened new Dicerna Pharmaceuticals, Inc. positions in Q3 2019 and 13 closed out, a net change of +15 holders.
- The largest Dicerna Pharmaceuticals, Inc. buyer in Q3 2019 was Eagle Asset Management, an estimated $25.2M added.
- The largest Dicerna Pharmaceuticals, Inc. seller in Q3 2019 was Bridger Management, an estimated $21.6M sold.
Based on aggregated 13F filings for Q3 2019.